Gaithersburg

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression4 trials
• Schizophrenia3 trials
• Bipolar disorder1 trial

Phase

• Phase 24 trials
• Phase 34 trials

Status

• Recruiting4 trials
• Completed3 trials
• Active, not recruiting1 trial

Lead sponsor

• Neurocrine Biosciences8 trials

Running trials

• Recruiting

  An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

  NCT07288320· Phase 2· Neurocrine Biosciences· Source

• Recruiting

  NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  NCT07114874· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06963021· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

  NCT06963034· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Neurocrine Biosciences· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia2 recruiting
• Bipolar disorder1 recruiting
• Depression1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

  NCT06267846· Phase 2· Neurocrine Biosciences· Source

• Completed

  Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

  NCT05545111· Phase 2· Neurocrine Biosciences· Source

• Completed

  Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

  NCT05203341· Phase 2· Neurocrine Biosciences· Source